Utama › Kanser Paru-paru Bukan Sel Kecil › Mississippi › Hattiesburg
Kajian klinikal Kanser Paru-paru Bukan Sel Kecil di Hattiesburg, MS
8 kajian untuk Kanser Paru-paru Bukan Sel Kecil sedang mencari peserta di lokasi dalam dan sekitar Hattiesburg (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Mengambil pesertaFasa 3
- Hattiesburg Clinic /ID# 248033, Hattiesburg
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Mengambil pesertaFasa 2
- Local Institution - 0180, Hattiesburg
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Mengambil pesertaFasa 3
- Hattiesburg Clinic Hematology/Oncology ( Site 0104), Hattiesburg
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Mengambil pesertaFasa 3
- Hattiesburg Clinic Hematology/Oncology, Hattiesburg
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Mengambil pesertaFasa 3
- Research Site, Hattiesburg
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Mengambil pesertaFasa 3
- Hattiesburg Clinic Hematology/Oncology, Hattiesburg
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Mengambil pesertaFasa 3
- Clinical Study Site, Hattiesburg
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Hattiesburg
Kajian Kanser Paru-paru Bukan Sel Kecil di bandar lain
- Houston, TX145 kajian
- New York City, NY121 kajian
- Arlington, VA104 kajian
- Nashville, TN97 kajian
- Boston, MA90 kajian
- Los Angeles, CA87 kajian
- St. Louis, MO73 kajian
- Chicago, IL61 kajian
- Baltimore, MD60 kajian
- San Antonio, TX59 kajian
- Columbus, OH57 kajian
- Washington, DC55 kajian
Kajian lain di Hattiesburg
- Penyakit Alzheimer4 kajian
- Kanser (semua jenis)4 kajian
- Kanser Kolorektal4 kajian
- Limfoma Folikular3 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.